Corporate Profile

CalciMedica is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies.

Learn More

Stock Information

Minimum 15 minutes delayed. Source:

Press Releases

20 Nov 24

CalciMedica Announces Presentations at Upcoming Medical Meetings

Prof. Robert Sutton to  deliver plenary presentation on Phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP) at American Pancreatic Association (APA) 2024 Annual Meeting Poster presentation on Phase 2b CARPO trial at Emergencies in Medicine (EIM) 2024 Meeting LA JOLLA, Calif. , Nov.
13 Nov 24

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora™ in acute pancreatitis (AP); Company expects to be in a position to initiate Phase 3 program in 2025 Enrollment ongoing in Phase 2 KOURAGE trial in acute kidney injury (AKI) and in Phase 2
07 Nov 24

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

LA JOLLA, Calif. , Nov. 7, 2024 /PRNewswire/ -- CalciMedica, Inc. ( CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and
30 Oct 24

CalciMedica Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and